Postpartum Hemorrhage Clinical Trial
Official title:
Prophylactic Methylergonovine in Patients Undergoing Cesarean Delivery With Twin Gestations: A Randomized Controlled Trial
Obstetrical hemorrhage (excessive bleeding related to pregnancy) is a leading cause of maternal morbidity (disease or symptom of disease) and mortality (death) worldwide with a significantly higher frequency and severity following cesarean delivery. Twin gestations (twin pregnancy) are at particularly higher risk for postpartum hemorrhage, yet the management of obstetrical bleeding following twin delivery remains identical to singleton delivery. The purpose of this study is to understand the effect of prophylactic methylergonovine on blood loss in scheduled twin pregnancy cesarean deliveries. Participants will be randomized (like tossing a coin) to Methylergonovine (investigational drug) or water with salt (saline) (placebo). Methylergonovine or saline will be given as an injection immediately after delivery.
Status | Recruiting |
Enrollment | 66 |
Est. completion date | September 30, 2024 |
Est. primary completion date | March 3, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | N/A to 65 Years |
Eligibility | Inclusion Criteria: - Twin gestation - Scheduled cesarean delivery (>=34 weeks) Exclusion criteria: - Patients with known hypertensive disease: history of chronic hypertension, gestational hypertension or preeclampsia with or without severe features - Use of protease inhibitors given known vasoconstrictive side effects with concomitant methylergonovine administration - Hypersensitivity to methylergonovine or any of the ingredients - Participating in another intervention study where the primary outcome includes postpartum bleeding or thromboembolism, or the study intervention directly affects postpartum bleeding or thromboembolism - Receipt of uterotonics, other than oxytocin, or planned or expected use of uterotonic prophylaxis - Non-elective cesarean delivery |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University Irving Medical Center | New York | New York |
Lead Sponsor | Collaborator |
---|---|
Columbia University |
United States,
Attilakos G, Psaroudakis D, Ash J, Buchanan R, Winter C, Donald F, Hunt LP, Draycott T. Carbetocin versus oxytocin for the prevention of postpartum haemorrhage following caesarean section: the results of a double-blind randomised trial. BJOG. 2010 Jul;117(8):929-36. doi: 10.1111/j.1471-0528.2010.02585.x. Epub 2010 May 19. — View Citation
Blitz MJ, Yukhayev A, Pachtman SL, Reisner J, Moses D, Sison CP, Greenberg M, Rochelson B. Twin pregnancy and risk of postpartum hemorrhage. J Matern Fetal Neonatal Med. 2020 Nov;33(22):3740-3745. doi: 10.1080/14767058.2019.1583736. Epub 2019 Mar 5. — View Citation
Chaudhuri P, Banerjee GB, Mandal A. Rectally administered misoprostol versus intravenous oxytocin infusion during cesarean delivery to reduce intraoperative and postoperative blood loss. Int J Gynaecol Obstet. 2010 Apr;109(1):25-9. doi: 10.1016/j.ijgo.2009.11.009. Epub 2010 Jan 13. — View Citation
Horowitz E, Yogev Y, Ben-Haroush A, Rabinerson D, Feldberg D, Kaplan B. Routine hemoglobin testing following an elective Cesarean section: is it necessary? J Matern Fetal Neonatal Med. 2003 Oct;14(4):223-5. doi: 10.1080/jmf.14.4.223.225. — View Citation
Masse N, Dexter F, Wong CA. Prophylactic Methylergonovine and Oxytocin Compared With Oxytocin Alone in Patients Undergoing Intrapartum Cesarean Birth: A Randomized Controlled Trial. Obstet Gynecol. 2022 Aug 1;140(2):181-186. doi: 10.1097/AOG.0000000000004857. Epub 2022 Jul 6. — View Citation
Osterman M, Hamilton B, Martin JA, Driscoll AK, Valenzuela CP. Births: Final Data for 2020. Natl Vital Stat Rep. 2021 Feb;70(17):1-50. — View Citation
Senturk S, Kagitci M, Balik G, Arslan H, Kir Sahin F. The Effect of the Combined Use of Methylergonovine and Oxytocin during Caesarean Section in the Prevention of Post-partum Haemorrhage. Basic Clin Pharmacol Toxicol. 2016 May;118(5):338-43. doi: 10.1111/bcpt.12500. Epub 2015 Nov 15. — View Citation
Sheehan SR, Montgomery AA, Carey M, McAuliffe FM, Eogan M, Gleeson R, Geary M, Murphy DJ; ECSSIT Study Group. Oxytocin bolus versus oxytocin bolus and infusion for control of blood loss at elective caesarean section: double blind, placebo controlled, randomised trial. BMJ. 2011 Aug 1;343:d4661. doi: 10.1136/bmj.d4661. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in maternal hemoglobin level | The change in maternal hemoglobin level as taken from blood samples. The change will be calculated from preoperative day 1 (baseline) to postoperative day 1. | Baseline and Postoperative Day 1 (Approximately 48 hours) | |
Secondary | Surgical time | Surgical time measured from the time of incision to closure | Intraoperative (Approximately 24 hours) | |
Secondary | Estimated blood loss | At the end of the surgery, the primary surgeon will estimate the blood loss throughout the case. | Intraoperative (Approximately 24 hours) | |
Secondary | Quantitative blood loss | Quantitative blood loss is calculated by weighing the used towels during the operation. The number is calculated by the circulating nurse in the operating room. | Intraoperative (Approximately 24 hours) | |
Secondary | Number of Participants with Postpartum hemorrhage | The number of participants with postpartum hemorrhage (defined as estimated blood loss >1000 cc) | Intraoperative (Approximately 24 hours) | |
Secondary | Number of Participants Requiring Use of Uterotonics | Number of participants given uterotonics, such as prostaglandins | Intraoperative (Approximately 24 hours) | |
Secondary | Number of Participants Requiring Use of Tranexamic acid Use of Tranexamic acid Use of Tranexamic acid | Number of participants given Tranexamic acid | Intraoperative (Approximately 24 hours) | |
Secondary | Number of Participants Requiring Use of Open-Label Methylergonovine | Number of participants requiring the use of any amount of open-label methylergonovine (not blinded study drug) | Intraoperative (Approximately 24 hours) | |
Secondary | Number of Participants Requiring Transfusion (Intraoperative) | Number of participants requiring transfusion of 1 or more units of packed red blood cells, including whole blood or cell saver. | Intraoperative (Approximately 24 hours) | |
Secondary | Composite Number of Surgical or Radiological Interventions | Composite number of surgical or radiological interventions (such as: laparotomy, evacuation of hematoma, hysterectomy, uterine packing, intrauterine balloon tamponade, interventional radiology) to control bleeding and related complications or maternal death. | Intraoperative (Approximately 24 hours) | |
Secondary | Number of Participants with Transfusion related acute lung injury (TRALI) | Number of participants with transfusion related acute lung injury (TRALI) | 6 weeks | |
Secondary | Number of Participants Requiring Transfusion (6 weeks) | Number of participants requiring transfusion of 1 or more units of fresh frozen plasma, cryoprecipitate, or platelets or administration of any factor concentrates. | 6 weeks | |
Secondary | Number of Participants with Acute Elevation of Serum Creatinine | Number of participants with acute elevation of serum creatinine of = 0.3 mg/dL | 48 hours | |
Secondary | Number of Postpartum Infectious Complications | Number of Postpartum infectious complications such as: endometritis, surgical site infection, pelvic abscess | 6 weeks | |
Secondary | Number of Participants with Admission to the Intensive Care Unit | Number of participants with admission to the intensive care unit for more than 24 hours | 6 weeks | |
Secondary | Length of stay | Length of stay measured from the time of hospital admission to hospital discharge. | 5 days | |
Secondary | Number of Participants Re-Admitted to the Hospital | The number of participants who experienced hospital re-admission | 6 weeks | |
Secondary | Apgar scores | Apgar score is a measure of the physical condition of a newborn infant. Scores range from 0-10 with a higher score indicating a better outcome; 5-minute Apgar score of 0-3 is low, 4-6 is moderately abnormal, and 7-10 is reassuring. | Time of delivery (Approximately 24 hours) | |
Secondary | Neonatal intensive care unit (NICU) admission | Number of newborns admitted to the neonatal intensive care unit (NICU). | Time of delivery (Approximately 24 hours) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03434444 -
In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol
|
N/A | |
Terminated |
NCT01980173 -
Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care
|
N/A | |
Not yet recruiting |
NCT06033170 -
Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage
|
N/A | |
Not yet recruiting |
NCT02319707 -
Management of the Third Stage of Labor
|
Phase 3 | |
Completed |
NCT02163616 -
Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study
|
Phase 3 | |
Recruiting |
NCT01600612 -
Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial
|
N/A | |
Completed |
NCT02079558 -
Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section
|
Phase 2 | |
Withdrawn |
NCT01108302 -
Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT00097123 -
RCT of Misoprostol for Postpartum Hemorrhage in India
|
N/A | |
Completed |
NCT02883673 -
Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage
|
N/A | |
Completed |
NCT02542813 -
Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers
|
Phase 1 | |
Completed |
NCT04201665 -
EMG for Uterotonic Efficiency Estimation
|
N/A | |
Terminated |
NCT03246919 -
Ideal Time of Oxytocin Infusion During Cesarean Section
|
Phase 4 | |
Not yet recruiting |
NCT05501106 -
Reducing Postpartum Hemorrhage After Vaginal Delivery
|
N/A | |
Completed |
NCT05429580 -
Prophylactic Tranexamic Acid Use After Vaginal Delivery
|
N/A | |
Terminated |
NCT03064152 -
Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery
|
N/A | |
Recruiting |
NCT05382403 -
Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage
|
N/A | |
Completed |
NCT03344302 -
Oxytocin Administration During Cesarean Section
|
Phase 4 | |
Completed |
NCT02910310 -
Introduction of UBT for PPH Management in Three Countries
|
N/A | |
Not yet recruiting |
NCT02853552 -
Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding
|
Phase 4 |